Juno Therapeutics Stock Price, News & Analysis (NASDAQ:JUNO)

$86.56 -0.08 (-0.09 %)
(As of 02/23/2018 09:30 AM ET)
Previous Close$86.56
Today's Range$86.56 - $86.68
52-Week Range$19.62 - $86.76
Volume5.45 million shs
Average Volume5.76 million shs
Market Capitalization$9.99 billion
P/E Ratio-25.61
Dividend YieldN/A
Beta3.43

About Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics logoJuno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Receive JUNO News and Ratings via Email

Sign-up to receive the latest news and ratings for JUNO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JUNO
CUSIPN/A
Phone206-582-1600

Debt

Debt-to-Equity Ratio0.01%
Current Ratio4.77%
Quick Ratio4.77%

Price-To-Earnings

Trailing P/E Ratio-25.6094674556213
Forward P/E Ratio-21.53
P/E GrowthN/A

Sales & Book Value

Annual Sales$79.36 million
Price / Sales125.79
Cash FlowN/A
Price / CashN/A
Book Value$10.18 per share
Price / Book8.50

Profitability

Trailing EPS($3.38)
Net Income$-245,580,000.00
Net Margins-332.05%
Return on Equity-32.54%
Return on Assets-24.87%

Miscellaneous

Employees553
Outstanding Shares115,330,000

Juno Therapeutics (NASDAQ:JUNO) Frequently Asked Questions

What is Juno Therapeutics' stock symbol?

Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."

How were Juno Therapeutics' earnings last quarter?

Juno Therapeutics Inc (NASDAQ:JUNO) posted its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Zacks' consensus estimate of ($0.80) by $0.07. The biopharmaceutical company had revenue of $44.80 million for the quarter, compared to analysts' expectations of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The company's quarterly revenue was up 115.4% on a year-over-year basis. During the same period last year, the firm earned ($0.57) EPS. View Juno Therapeutics' Earnings History.

When will Juno Therapeutics make its next earnings announcement?

Juno Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Juno Therapeutics.

Where is Juno Therapeutics' stock going? Where will Juno Therapeutics' stock price be in 2018?

17 brokers have issued 1-year target prices for Juno Therapeutics' shares. Their forecasts range from $23.73 to $87.00. On average, they expect Juno Therapeutics' stock price to reach $54.41 in the next year. View Analyst Ratings for Juno Therapeutics.

What are Wall Street analysts saying about Juno Therapeutics stock?

Here are some recent quotes from research analysts about Juno Therapeutics stock:

  • 1. According to Zacks Investment Research, "Juno remains on track with its pipeline and continues to pursue acquisitions and licensing agreements. The company’s deal with Celgene for global development and commercialization of immunotherapies is encouraging. Moreover, the company’s targeted, cancer immunotherapy is a highly lucrative area as these therapies have the potential to change the treatment paradigm for cancer. Shares of the company have also outperformed the industry in the last one year. However, the company suffered a huge setback with discontinuation of the development of cancer candidate, JCAR015, due to the toxicity witnessed in a phase II ROCKET study. Also, increased competition in the immunotherapy space is a matter of concern for the company. Juno’s pipeline candidates are still a few steps away from approval and hence, any setback would weigh heavily on the stock." (2/21/2018)
  • 2. Maxim Group analysts commented, "The American Society of Hematology (ASH) is now over, and while we saw bluebird’s (BLUE – $190.95 – Hold) valuation rise to over $9B on strong data in CAR-T and gene therapy, Juno’s valuation has seen a retracement from its pre- ASH peak of $7B, to $5B on what is incremental data for lead CAR candidate JCAR017." (12/13/2017)

Are investors shorting Juno Therapeutics?

Juno Therapeutics saw a decline in short interest in January. As of January 31st, there was short interest totalling 3,637,584 shares, a decline of 58.8% from the January 12th total of 8,834,492 shares. Based on an average daily volume of 10,485,500 shares, the short-interest ratio is currently 0.3 days. Approximately 4.3% of the company's stock are sold short.

Who are some of Juno Therapeutics' key competitors?

Who are Juno Therapeutics' key executives?

Juno Therapeutics' management team includes the folowing people:

  • Howard H. Pien, Independent Chairman of the Board (Age 59)
  • Hans Edgar Bishop, President, Chief Executive Officer, Director (Age 53)
  • Sunil Agarwal M.D., President of Research & Development (Age 47)
  • Steven D. Harr M.D., Chief Financial Officer, Head of Corporate Development (Age 46)
  • Hyam I. Levitsky M.D, Executive vice president - Research, chief scientific officer (Age 54)
  • Robert W. Azelby, Executive Vice President, Chief Commercial Officer (Age 49)
  • Ann Lee Ph.D., Executive Vice President - Technical Operations
  • Patrick Y. Yang, Executive Vice President (Age 69)
  • Cynthia Elkins, Chief Information Officer
  • Bernard J. Cassidy, General Counsel, Secretary (Age 62)

When did Juno Therapeutics IPO?

(JUNO) raised $153 million in an initial public offering (IPO) on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager.

Who owns Juno Therapeutics stock?

Juno Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include CELGENE CORP (9.70%), BAILLIE GIFFORD & COMPANY (9.24%), Crestline Management LP (6.62%), BlackRock Inc. (4.19%), Jennison Associates LLC (1.51%) and ArrowMark Colorado Holdings LLC (1.05%). Company insiders that own Juno Therapeutics stock include Anthony B Evnin, Bernard J Cassidy, Douglas K Bratton, Hans Edgar Bishop, Hyam Levitsky, Jay T Flatley, Richard Klausner, Robert Azelby, Steve Harr and Sunil Agarwal. View Institutional Ownership Trends for Juno Therapeutics.

Who sold Juno Therapeutics stock? Who is selling Juno Therapeutics stock?

Juno Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Crestline Management LP, Omega Fund Management LLC, First Trust Advisors LP, Jennison Associates LLC, D.A. Davidson & CO., ArrowMark Colorado Holdings LLC, Two Sigma Investments LP and Vident Investment Advisory LLC. Company insiders that have sold Juno Therapeutics company stock in the last year include Bernard J Cassidy, Douglas K Bratton, Hans Edgar Bishop, Richard Klausner, Robert Azelby, Steve Harr and Sunil Agarwal. View Insider Buying and Selling for Juno Therapeutics.

Who bought Juno Therapeutics stock? Who is buying Juno Therapeutics stock?

Juno Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., ARK Investment Management LLC, Amundi Pioneer Asset Management Inc., Deutsche Bank AG, BBR Partners LLC, Geode Capital Management LLC, Schwab Charles Investment Management Inc. and Raymond James & Associates. Company insiders that have bought Juno Therapeutics stock in the last two years include Anthony B Evnin and Jay T Flatley. View Insider Buying and Selling for Juno Therapeutics.

How do I buy Juno Therapeutics stock?

Shares of Juno Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Juno Therapeutics' stock price today?

One share of Juno Therapeutics stock can currently be purchased for approximately $86.56.

How big of a company is Juno Therapeutics?

Juno Therapeutics has a market capitalization of $9.99 billion and generates $79.36 million in revenue each year. The biopharmaceutical company earns $-245,580,000.00 in net income (profit) each year or ($3.38) on an earnings per share basis. Juno Therapeutics employs 553 workers across the globe.

How can I contact Juno Therapeutics?

Juno Therapeutics' mailing address is 400 DEXTER AVENUE NORTH SUITE 1200, SEATTLE WA, 98109. The biopharmaceutical company can be reached via phone at 206-582-1600.


MarketBeat Community Rating for Juno Therapeutics (JUNO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  350 (Vote Outperform)
Underperform Votes:  244 (Vote Underperform)
Total Votes:  594
MarketBeat's community ratings are surveys of what our community members think about Juno Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Juno Therapeutics (NASDAQ:JUNO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.122.122.472.33
Ratings Breakdown: 0 Sell Rating(s)
15 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
15 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $54.41$54.41$46.41$29.37
Price Target Upside: 36.63% downside36.63% downside20.64% downside1.70% downside

Juno Therapeutics (NASDAQ:JUNO) Consensus Price Target History

Price Target History for Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ:JUNO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018Standpoint ResearchReiterated RatingBuy -> HoldLowView Rating Details
1/24/2018BarclaysDowngradeOverweight -> Equal Weight$55.00 -> $87.00LowView Rating Details
1/23/2018Leerink SwannDowngradeOutperform -> Market Perform$56.00 -> $87.00LowView Rating Details
1/23/2018Raymond James FinancialDowngradeOutperform -> HoldLowView Rating Details
1/22/2018SunTrust BanksReiterated RatingBuy -> HoldLowView Rating Details
1/22/2018Needham & Company LLCDowngradeBuy -> HoldLowView Rating Details
1/22/2018GuggenheimDowngradeBuy -> NeutralLowView Rating Details
1/17/2018CitigroupDowngradeBuy -> NeutralHighView Rating Details
1/17/2018WedbushDowngradeOutperform -> NeutralHighView Rating Details
1/17/2018Wells Fargo & CoReiterated RatingMarket Perform$54.00 -> $63.00HighView Rating Details
1/11/2018JPMorgan Chase & Co.Reiterated RatingHoldHighView Rating Details
12/13/2017Maxim GroupSet Price TargetBuy$56.00HighView Rating Details
11/3/2017CowenReiterated RatingBuyN/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral -> Neutral$44.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$27.00 -> $43.00N/AView Rating Details
8/28/2017BTIG ResearchUpgradeSell -> NeutralHighView Rating Details
5/18/2017FBR & CoReiterated RatingHoldMediumView Rating Details
2/27/2016Deutsche BankInitiated CoverageBuyN/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Juno Therapeutics (NASDAQ:JUNO) Earnings History and Estimates Chart

Earnings by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ JUNO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($1.01)N/AView Earnings Details
11/1/2017Q3 2017($0.80)($0.73)$18.12 million$44.80 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.72)($0.96)$15.59 million$21.30 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.70)($0.71)$16.00 million$19.30 millionViewListenView Earnings Details
3/1/2017Q416($0.61)($0.65)$14.57 million$21.15 millionViewListenView Earnings Details
11/9/2016Q316($0.52)($0.57)$10.98 million$20.80 millionViewListenView Earnings Details
8/4/2016Q216($0.41)($0.64)$14.26 million$27.60 millionViewListenView Earnings Details
5/9/2016Q116($0.52)($0.78)$4.83 million$9.80 millionViewListenView Earnings Details
2/29/2016Q415($0.54)($0.53)$4.79 million$4.15 millionViewListenView Earnings Details
11/10/2015Q315($0.41)($0.53)$6.41 million$1.60 millionViewListenView Earnings Details
8/12/2015Q215($0.37)($0.35)$2.03 million$12.50 millionViewListenView Earnings Details
5/11/2015Q115($0.35)($0.30)ViewListenView Earnings Details
3/18/2015Q414($0.33)($1.73)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Juno Therapeutics (NASDAQ:JUNO) Earnings Estimates

2018 EPS Consensus Estimate: ($4.05)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.00)($1.00)($1.00)
Q2 20181($0.97)($0.97)($0.97)
Q3 20181($0.99)($0.99)($0.99)
Q4 20181($1.09)($1.09)($1.09)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Juno Therapeutics (NASDAQ:JUNO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Juno Therapeutics (NASDAQ JUNO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.08%
Institutional Ownership Percentage: 71.49%
Insider Trades by Quarter for Juno Therapeutics (NASDAQ:JUNO)
Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ JUNO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/12/2018Robert AzelbyEVPSell4,157$85.55$355,631.3589,614View SEC Filing  
2/8/2018Robert AzelbyEVPSell3,497$85.77$299,937.6993,771View SEC Filing  
2/1/2018Robert AzelbyEVPSell4,167$85.78$357,445.2696,471View SEC Filing  
1/22/2018Robert AzelbyEVPSell102,539$86.25$8,843,988.75173,371View SEC Filing  
1/17/2018Robert AzelbyEVPSell29,131$68.61$1,998,677.9173,330View SEC Filing  
1/16/2018Hans Edgar BishopCEOSell270,250$46.17$12,477,442.502,772,679View SEC Filing  
1/8/2018Richard KlausnerDirectorSell12,724$48.21$613,424.04741,499View SEC Filing  
12/21/2017Richard KlausnerDirectorSell36,000$44.76$1,611,360.00744,392View SEC Filing  
12/21/2017Steve HarrCFOSell8,750$44.76$391,650.00772,082View SEC Filing  
12/18/2017Robert AzelbyEVPSell1,816$44.96$81,647.3670,832View SEC Filing  
11/2/2017Robert AzelbyEVPSell6,666$54.95$366,296.7079,998View SEC Filing  
10/2/2017Sunil AgarwalInsiderSell7,285$44.76$326,076.60View SEC Filing  
9/14/2017Bernard J CassidyGeneral CounselSell28,000$44.92$1,257,760.0055,970View SEC Filing  
9/13/2017Robert AzelbyEVPSell12,850$44.95$577,607.5037,439View SEC Filing  
9/7/2017Richard KlausnerDirectorSell12,000$42.66$511,920.00783,536View SEC Filing  
8/29/2017Robert AzelbyEVPSell12,869$39.95$514,116.5550,289View SEC Filing  
8/7/2017Richard KlausnerDirectorSell12,000$30.34$364,080.00788,985View SEC Filing  
7/13/2017Douglas K BrattonMajor ShareholderSell8,000,000$27.00$216,000,000.00View SEC Filing  
7/7/2017Richard KlausnerDirectorSell24,000$29.39$705,360.00824,985View SEC Filing  
7/3/2017Steve HarrCFOSell8,750$30.00$262,500.00736,189View SEC Filing  
6/27/2017Steve HarrCFOSell8,750$30.00$262,500.00736,189View SEC Filing  
6/20/2017Anthony B EvninDirectorBuy9,000$24.40$219,600.0066,301View SEC Filing  
5/30/2017Jay T FlatleyDirectorBuy10,000$22.92$229,200.00View SEC Filing  
5/26/2017Jay T FlatleyDirectorBuy20,000$24.76$495,200.00View SEC Filing  
3/10/2017Anthony B EvninDirectorBuy8,000$22.11$176,880.0056,990View SEC Filing  
11/10/2016Robert AzelbyEVPSell12,921$24.14$311,912.9448,640View SEC Filing  
9/27/2016Hans Edgar BishopCEOSell44,000$33.00$1,452,000.002,490,859View SEC Filing  
9/21/2016Hans Edgar BishopCEOSell84,035$30.28$2,544,579.802,518,537View SEC Filing  
9/8/2016Hans Edgar BishopCEOSell23,042$30.06$692,642.522,541,151View SEC Filing  
6/24/2016Richard KlausnerDirectorSell12,000$40.71$488,520.00846,799View SEC Filing  
6/17/2016Hyam LevitskyEVPSell12,418$42.77$531,117.86117,000View SEC Filing  
6/10/2016Steve HarrCFOSell30,000$43.32$1,299,600.00716,052View SEC Filing  
6/9/2016Hans Edgar BishopCEOSell90,750$46.42$4,212,615.002,704,609View SEC Filing  
5/19/2016Bernard J CassidyGeneral CounselSell3,116$39.03$121,617.4855,511View SEC Filing  
5/18/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00858,799View SEC Filing  
4/19/2016Bernard J CassidyGeneral CounselSell3,200$43.12$137,984.0057,933View SEC Filing  
4/15/2016Richard KlausnerDirectorSell12,000$42.90$514,800.00872,792View SEC Filing  
3/28/2016Anthony B EvninDirectorBuy8,000$36.58$292,640.0050,000View SEC Filing  
3/22/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00882,499View SEC Filing  
3/18/2016Bernard J CassidyGeneral CounselSell3,200$38.18$122,176.0061,865View SEC Filing  
3/4/2016Steve HarrInsiderSell5,000$45.00$225,000.00730,000View SEC Filing  
3/2/2016Richard KlausnerDirectorSell24,000$40.42$970,080.00895,259View SEC Filing  
3/1/2016Douglas K BrattonMajor ShareholderSell8,600,000$39.00$335,400,000.00View SEC Filing  
3/1/2016Steve HarrInsiderSell30,000$37.58$1,127,400.00762,987View SEC Filing  
2/19/2016Bernard J. CassidyGeneral CounselSell3,200$34.50$110,400.0063,683View SEC Filing  
1/19/2016Bernard J. CassidyGeneral CounselSell3,200$33.55$107,360.0066,883View SEC Filing  
12/18/2015Bernard J. CassidyGeneral CounselSell3,200$45.39$145,248.0070,083View SEC Filing  
12/10/2015Steve HarrinsiderSell35,000$46.43$1,625,050.00765,000View SEC Filing  
11/19/2015Bernard J. CassidyGeneral CounselSell3,200$52.97$169,504.0071,200View SEC Filing  
11/13/2015Richard KlausnerDirectorSell12,000$49.51$594,120.00930,499View SEC Filing  
10/19/2015Bernard J. CassidyGeneral CounselSell3,200$49.85$159,520.0074,400View SEC Filing  
10/15/2015Richard KlausnerDirectorSell8,000$50.00$400,000.00942,499View SEC Filing  
10/12/2015Richard KlausnerDirectorSell16,000$50.00$800,000.00950,499View SEC Filing  
9/18/2015Bernard J. CassidyGeneral CounselSell11,850$42.50$503,625.0077,600View SEC Filing  
8/19/2015Bernard J. CassidyGeneral CounselSell11,850$40.15$475,777.5089,450View SEC Filing  
7/17/2015Bernard J CassidyGeneral CounselSell11,850$50.55$599,017.50View SEC Filing  
7/15/2015Richard KlausnerDirectorSell8,000$53.34$426,720.00View SEC Filing  
7/2/2015Douglas K BrattonMajor ShareholderSell40,000$54.75$2,190,000.00View SEC Filing  
6/26/2015Anthony B EvninDirectorSell583,333$48.11$28,064,150.63View SEC Filing  
6/24/2015Bernard J CassidyGeneral CounselSell11,850$51.34$608,379.00View SEC Filing  
6/24/2015Douglas K BrattonMajor ShareholderSell270,000$51.13$13,805,100.00View SEC Filing  
6/23/2015Richard KlausnerDirectorSell8,000$52.29$418,320.00View SEC Filing  
6/18/2015Anthony B EvninDirectorSell583,333$52.88$30,846,649.04View SEC Filing  
12/23/2014Douglas K BrattonMajor ShareholderBuy625,000$24.00$15,000,000.00View SEC Filing  
12/23/2014Hal BarronDirectorBuy100,000$24.00$2,400,000.00View SEC Filing  
12/19/2014Douglas K BrattonMajor ShareholderBuy625,000$25.00$15,625,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Juno Therapeutics (NASDAQ JUNO) News Headlines

Source:
DateHeadline
Form SC 14D9/A Juno Therapeutics, Inc. Filed by: Juno Therapeutics, Inc. - StreetInsider.comForm SC 14D9/A Juno Therapeutics, Inc. Filed by: Juno Therapeutics, Inc. - StreetInsider.com
www.streetinsider.com - February 23 at 8:35 AM
Celgene Gets Antitrust Clearance For Juno Therapeutics Acquisition ... - NasdaqCelgene Gets Antitrust Clearance For Juno Therapeutics Acquisition ... - Nasdaq
www.nasdaq.com - February 23 at 8:35 AM
Blog Exposure - Celgene Gets Antitrust Clearance for Juno’s AcquisitionBlog Exposure - Celgene Gets Antitrust Clearance for Juno’s Acquisition
finance.yahoo.com - February 23 at 8:35 AM
Form SC 14D9/A Juno Therapeutics, Inc. Filed by: Juno Therapeutics, Inc.Form SC 14D9/A Juno Therapeutics, Inc. Filed by: Juno Therapeutics, Inc.
www.streetinsider.com - February 22 at 8:30 AM
Juno Therapeutics (JUNO) Raised to "Hold" at Zacks Investment ResearchJuno Therapeutics (JUNO) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 21 at 2:11 PM
Celgene Gets Antitrust Clearance For Juno Therapeutics AcquisitionCelgene Gets Antitrust Clearance For Juno Therapeutics Acquisition
www.nasdaq.com - February 21 at 8:31 AM
Celgene Receives Antitrust Clearance for Juno AcquisitionCelgene Receives Antitrust Clearance for Juno Acquisition
finance.yahoo.com - February 21 at 8:31 AM
Whats in Store for Juno Therapeutics (JUNO) in Q4 Earnings?What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?
www.msn.com - February 20 at 5:38 PM
What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?
finance.yahoo.com - February 20 at 5:38 PM
Juno Therapeutics (JUNO) Set to Announce Earnings on TuesdayJuno Therapeutics (JUNO) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:12 AM
Nektar Gets a Payday But No Mega-Buyout - BloombergNektar Gets a Payday But No Mega-Buyout - Bloomberg
www.bloomberg.com - February 15 at 8:13 AM
Juno Therapeutics Inc (JUNO) EVP Robert Azelby Sells 4,157 SharesJuno Therapeutics Inc (JUNO) EVP Robert Azelby Sells 4,157 Shares
www.americanbankingnews.com - February 14 at 9:40 PM
Why Biotech Stocks Soared in Trump's First Year in OfficeWhy Biotech Stocks Soared in Trump's First Year in Office
finance.yahoo.com - February 11 at 9:39 AM
Form 4 Juno Therapeutics, Inc. For: Feb 07 Filed by: Harr SteveForm 4 Juno Therapeutics, Inc. For: Feb 07 Filed by: Harr Steve
www.streetinsider.com - February 10 at 9:40 AM
Juno Therapeutics Inc (JUNO) Short Interest UpdateJuno Therapeutics Inc (JUNO) Short Interest Update
www.americanbankingnews.com - February 10 at 2:24 AM
Juno Therapeutics Inc (JUNO) EVP Robert Azelby Sells 3,497 SharesJuno Therapeutics Inc (JUNO) EVP Robert Azelby Sells 3,497 Shares
www.americanbankingnews.com - February 9 at 9:28 PM
Celgene Prices $4.5 Bln Of Senior Unsecured Notes - Quick FactsCelgene Prices $4.5 Bln Of Senior Unsecured Notes - Quick Facts
www.nasdaq.com - February 9 at 9:48 AM
Zacks: Analysts Anticipate Juno Therapeutics Inc (JUNO) to Post -$1.15 EPSZacks: Analysts Anticipate Juno Therapeutics Inc (JUNO) to Post -$1.15 EPS
www.americanbankingnews.com - February 4 at 1:16 AM
Juno Therapeutics Inc (JUNO) EVP Sells $357,445.26 in StockJuno Therapeutics Inc (JUNO) EVP Sells $357,445.26 in Stock
www.americanbankingnews.com - February 2 at 9:28 PM
BRIEF-Celgene Corp Commences Tender Offer For Juno TherapeuticsBRIEF-Celgene Corp Commences Tender Offer For Juno Therapeutics
www.reuters.com - February 2 at 9:50 AM
Juno Therapeutics Inc (JUNO) Given Average Rating of "Hold" by AnalystsJuno Therapeutics Inc (JUNO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - February 2 at 5:46 AM
Is Celgene's Big Bet on CAR-T Smart?Is Celgene's Big Bet on CAR-T Smart?
finance.yahoo.com - February 1 at 3:48 PM
Juno Therapeutics Inc (JUNO) Director Purchases $229,200.00 in StockJuno Therapeutics Inc (JUNO) Director Purchases $229,200.00 in Stock
www.americanbankingnews.com - January 30 at 6:32 PM
Juno Therapeutics (JUNO) Rating Lowered to Equal Weight at BarclaysJuno Therapeutics (JUNO) Rating Lowered to Equal Weight at Barclays
www.americanbankingnews.com - January 28 at 6:36 PM
3 Reasons Celgene's Investors Should Applaud the Juno Therapeutics Buyout3 Reasons Celgene's Investors Should Applaud the Juno Therapeutics Buyout
finance.yahoo.com - January 27 at 3:52 PM
5 Things Celgene's Management Just Said That You'll Want to Know5 Things Celgene's Management Just Said That You'll Want to Know
finance.yahoo.com - January 27 at 10:10 AM
Form SC TO-C Juno Therapeutics, Inc. Filed by: CELGENE CORP /DE/Form SC TO-C Juno Therapeutics, Inc. Filed by: CELGENE CORP /DE/
www.streetinsider.com - January 26 at 10:00 AM
Celgene Says Juno, Impact Deals Wont Be Its LastCelgene Says Juno, Impact Deals Won't Be Its Last
finance.yahoo.com - January 25 at 3:50 PM
Juno Therapeutics Inc (NASDAQ:JUNO): Financial Strength AnalysisJuno Therapeutics Inc (NASDAQ:JUNO): Financial Strength Analysis
finance.yahoo.com - January 25 at 9:50 AM
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Juno Therapeutics, Inc. - JUNOSHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Juno Therapeutics, Inc. - JUNO
finance.yahoo.com - January 25 at 9:50 AM
Celgenes profit, sales beat on continued Revlimid strengthCelgene's profit, sales beat on continued Revlimid strength
finance.yahoo.com - January 25 at 9:50 AM
Juno Therapeutics Inc (JUNO) EVP Sells $8,843,988.75 in StockJuno Therapeutics Inc (JUNO) EVP Sells $8,843,988.75 in Stock
www.americanbankingnews.com - January 24 at 9:08 PM
WeissLaw LLP Investigates Juno Therapeutics Inc. AcquisitionWeissLaw LLP Investigates Juno Therapeutics Inc. Acquisition
finance.yahoo.com - January 24 at 3:59 PM
Standpoint Research Lowers Juno Therapeutics (JUNO) to HoldStandpoint Research Lowers Juno Therapeutics (JUNO) to Hold
www.americanbankingnews.com - January 24 at 10:26 AM
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Juno Therapeutics, Inc. - PR Newswire (press release)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Juno Therapeutics, Inc. - PR Newswire (press release)
www.prnewswire.com - January 24 at 8:14 AM
Mid-Day Market Update: Juno Therapeutics Surges On Acquisition ... - NasdaqMid-Day Market Update: Juno Therapeutics Surges On Acquisition ... - Nasdaq
www.nasdaq.com - January 24 at 8:14 AM
SHAREHOLDER ALERT: Rigrodsky & Long, PA Announces Investigation of Juno Therapeutics, Inc. Buyout - Business Wire (press release)SHAREHOLDER ALERT: Rigrodsky & Long, PA Announces Investigation of Juno Therapeutics, Inc. Buyout - Business Wire (press release)
www.businesswire.com - January 24 at 8:14 AM
Blog Exposure - Celgene acquires Juno Therapeutics for $9 billion for its portfolio of CAR T-cell therapiesBlog Exposure - Celgene acquires Juno Therapeutics for $9 billion for its portfolio of CAR T-cell therapies
finance.yahoo.com - January 24 at 8:14 AM
Celgene's Been Selling Shares in This BiotechCelgene's Been Selling Shares in This Biotech
finance.yahoo.com - January 24 at 8:14 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Juno Therapeutics, Inc. to Celgene Corp. is Fair to ShareholdersINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Juno Therapeutics, Inc. to Celgene Corp. is Fair to Shareholders
finance.yahoo.com - January 23 at 5:19 PM
Celgene (CELG) to Acquire Juno Therapeutics for $9 BillionCelgene (CELG) to Acquire Juno Therapeutics for $9 Billion
finance.yahoo.com - January 23 at 5:19 PM
Superior Sales Growth Make Juno Therapeutics (JUNO) a BuySuperior Sales Growth Make Juno Therapeutics (JUNO) a Buy
investorplace.com - January 23 at 12:56 PM
Juno Therapeutics (JUNO) Given Market Perform Rating at Leerink SwannJuno Therapeutics (JUNO) Given Market Perform Rating at Leerink Swann
www.americanbankingnews.com - January 23 at 9:10 AM
Juno Therapeutics (JUNO) Lowered to Hold at SunTrust BanksJuno Therapeutics (JUNO) Lowered to Hold at SunTrust Banks
www.americanbankingnews.com - January 22 at 8:34 PM
Celgene diversifies portfolio with purchase of Juno TherapeuticsCelgene diversifies portfolio with purchase of Juno Therapeutics
www.bizjournals.com - January 22 at 4:02 PM
2018’s M&A Frenzy Has Begun: Juno Therapeutics Inc (JUNO), Celgene Corporation (CELG)2018’s M&A Frenzy Has Begun: Juno Therapeutics Inc (JUNO), Celgene Corporation (CELG)
finance.yahoo.com - January 22 at 4:02 PM
Celgene to Buy Juno Therapeutics for $9 BillionCelgene to Buy Juno Therapeutics for $9 Billion
www.wsj.com - January 22 at 4:02 PM
Celgene Acquires Company Investigating Cancer Warfare DrugCelgene Acquires Company Investigating Cancer Warfare Drug
finance.yahoo.com - January 22 at 4:02 PM
Why Biotech's $20B Merger Monday May Not Be a Home RunWhy Biotech's $20B Merger Monday May Not Be a Home Run
finance.yahoo.com - January 22 at 4:02 PM
Celgene's $9 Billion Buyout of Juno: Is It a Good Deal for Investors?Celgene's $9 Billion Buyout of Juno: Is It a Good Deal for Investors?
finance.yahoo.com - January 22 at 4:02 PM

SEC Filings

Juno Therapeutics (NASDAQ:JUNO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Juno Therapeutics (NASDAQ:JUNO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Juno Therapeutics (NASDAQ JUNO) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.